U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
April 17, 2024 08:00 ET
|
Kaléo
Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...
U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure
July 18, 2023 08:00 ET
|
Kaléo
Richmond, Virginia, July 18, 2023 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company, today announced their selection by the U.S. Department of Defense (DOD) Joint Program...
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
September 26, 2022 16:12 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA®...